ARTICLE | Company News

Shire exercises option with arGEN-X

December 12, 2014 2:54 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) exercised its option to advance one or more product candidates from its 2012 antibody partnership with arGEN-X N.V. (Euronext:ARGX). arGEN-X will receive an undisclosed milestone payment from Shire.

Shire's decision follows the partners' expansion of the deal in June, under which arGEN-X will use its suite of human antibody discovery technologies to discover antibodies against multiple undisclosed targets selected by Shire, which will be responsible for clinical development and commercialization (see BioCentury, June 30). ...